FLT3 and acute myeloid leukemia: Importantly, a genome-wide CRISPR-Cas9 knockout screen identified the enzyme glutaminase (GLS) as a major metabolic vulnerability in FLT3-ITD-mutated AML cells treated with FLT3 tyrosine kinase inhibitors (73).